New breath test could catch cystic fibrosis lung damage early in young children
NCT ID NCT02342951
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether a non-invasive breathing test called the lung clearance index (LCI) can detect early lung disease in young children with cystic fibrosis. Researchers tested 53 children aged 3 to 6 years and compared the results with CT scans and other lung function tests. The goal was to see if LCI could help doctors start treatment sooner and choose the best therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a simple, non-invasive way to catch lung problems early in young children with cystic fibrosis, allowing for earlier treatment.
- What could go wrong
- This is a small, completed observational study, not a treatment trial. The test may not prove reliable enough for routine use, and results may not apply to all children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
53 people
The number who actually took part.
- Started
-
Apr 2014
- Finished
-
Jul 2019
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
3 to 6 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Children with typical cystic fibrosis (sweat chloride level \>60 mEq/l) followed in reference centre participating to the study * From 3 to 6 years old * Children with a planned annual assessment that required thoracic computed tomography and lung function test * Children with informed and non opposed parents Exclusion Criteria: * Children with atypical cystic fibrosis * Children with bronchial exacerbation dating less than 2 weeks * Children with severe associated disease
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Necker-Enfants Malades
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- Can a simple questionnaire reveal why some cystic fibrosis patients skip physiotherapy?
- Cystic fibrosis diabetes: do gut hormones and genes hold the key?
- Can a special lung scan catch cystic fibrosis damage earlier than standard tests?
- Can a pill replace the liquid? testing a new form of cystic fibrosis drug
- Triple therapy under the microscope: does it transform cystic fibrosis care?